Literature DB >> 19744598

Nephrogenic systemic fibrosis: clinical picture and treatment.

Peter Marckmann1, Lone Skov.   

Abstract

The classic hallmark symptoms of advanced nephrogenic systemic fibrosis (NSF) (skin thickening, hardening and hyperpigmentation, and disabling contractures in renal failure patients) in temporal association with Gd-based contrast agent (GBCA) exposure are almost pathognomonic of NSF. Less obvious cases may be diagnosed on the basis of history of early GBCA-related NSF symptoms (warm swellings, pain, discoloration, itching of lower legs), signs of multiorgan involvement (lungs, nervous system), the exclusion of differential diagnoses, including scleromyxedema and systemic sclerosis, and the histology of deep skin biopsies. Symptomatic treatment with intensive physiotherapy and painkillers is important, but there is no known curative medical treatment. Spontaneous remission of NSF symptoms may occur with recovery of renal function after an episode of acute renal failure, or with kidney transplantation of chronic renal failure patients.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19744598     DOI: 10.1016/j.rcl.2009.05.004

Source DB:  PubMed          Journal:  Radiol Clin North Am        ISSN: 0033-8389            Impact factor:   2.303


  14 in total

1.  Extensive pneumatized air cells causing susceptibility artifacts in the petrosus part of the ICA.

Authors:  M R McCoy; E Broussalis; M Killer; J Steinbacher; F Klausner
Journal:  Clin Neuroradiol       Date:  2015-05-05       Impact factor: 3.649

2.  Scleroderma Mimickers.

Authors:  Nadia D Morgan; Laura K Hummers
Journal:  Curr Treatm Opt Rheumatol       Date:  2016-02-05

3.  Advancing pharmacovigilance through academic-legal collaboration: the case of gadolinium-based contrast agents and nephrogenic systemic fibrosis-a Research on Adverse Drug Events and Reports (RADAR) report.

Authors:  B J Edwards; A E Laumann; B Nardone; F H Miller; J Restaino; D W Raisch; J M McKoy; J A Hammel; K Bhatt; K Bauer; A T Samaras; M J Fisher; C Bull; E Saddleton; S M Belknap; H S Thomsen; E Kanal; S E Cowper; A K Abu Alfa; D P West
Journal:  Br J Radiol       Date:  2014-10       Impact factor: 3.039

4.  Distribution of estimated glomerular filtration rate (eGFR) values in patients receiving contrast-enhanced magnetic resonance imaging.

Authors:  Keigo Shimoji; Shigeki Aoki; Atsushi Nakanishi; Michimasa Suzuki; Masaaki Hori; Syuji Sato; Haruyoshi Hoshito; Shinsuke Kyogoku; Narisumi Cho; Yutaka Ozaki; Masaru Suzuki; Ryohei Kuwatsuru; Keisuke Sasai
Journal:  Jpn J Radiol       Date:  2011-12-27       Impact factor: 2.374

Review 5.  Renal imaging in patients with renal impairment.

Authors:  Jason A Poff; Elizabeth M Hecht; Parvati Ramchandani
Journal:  Curr Urol Rep       Date:  2011-02       Impact factor: 3.092

Review 6.  Role of Cardiac Imaging (CT/MR) Before and After RF Catheter Ablation in Patients with Atrial Fibrillation.

Authors:  Aravindan Kolandaivelu
Journal:  J Atr Fibrillation       Date:  2012-08-20

Review 7.  Scleroderma mimics.

Authors:  Jennifer Nashel; Virginia Steen
Journal:  Curr Rheumatol Rep       Date:  2012-02       Impact factor: 4.592

Review 8.  Fibroblasts and myofibroblasts in renal fibrosis.

Authors:  Soma Meran; Robert Steadman
Journal:  Int J Exp Pathol       Date:  2011-02-28       Impact factor: 1.925

9.  StatSensor-i point-of-care creatinine analyzer may identify patients at high-risk of contrast-induced nephropathy.

Authors:  Akitoshi Inoue; Norihisa Nitta; Shinichi Ohta; Katsuji Imoto; Michio Yamasaki; Mitsuru Ikeda; Kiyoshi Murata
Journal:  Exp Ther Med       Date:  2017-04-26       Impact factor: 2.447

Review 10.  Nephrogenic systemic fibrosis and gadolinium-based contrast media: updated ESUR Contrast Medium Safety Committee guidelines.

Authors:  Henrik S Thomsen; Sameh K Morcos; Torsten Almén; Marie-France Bellin; Michele Bertolotto; Georg Bongartz; Olivier Clement; Peter Leander; Gertraud Heinz-Peer; Peter Reimer; Fulvio Stacul; Aart van der Molen; Judith A W Webb
Journal:  Eur Radiol       Date:  2012-08-04       Impact factor: 5.315

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.